Finasteride in Hair Restoration: Evidence, Safety and Patient-Centred Use

Finasteride is a 5α-reductase inhibitor used in male pattern hair loss. It blocks the conversion of testosterone to dihydrotestosterone (DHT), the androgen that drives follicular miniaturisation, and can slow progression and support regrowth in many men with mild to moderate androgenetic alopecia. It is a prescription medicine, it is not appropriate for everyone, and it carries risks that regulators in four jurisdictions have strengthened their warnings about since 2023. This page sets out what the evidence supports, what it does not, and what we tell every patient before they decide.

Written and medically reviewed by Op. Dr. Ahmet Dilber, Consultant Plastic, Reconstructive and Aesthetic Surgeon, Hair of Istanbul. Turkish Ministry of Health specialist registration no. 128474. Version 1.0, January 2026. Last reviewed: September 2026. Sources listed at the end of this page.

How Finasteride Works

Androgenetic alopecia is the most common cause of progressive thinning in men. It is driven by genetic predisposition combined with androgen signalling in susceptible follicles — particularly the effects of DHT. Terminal hairs are gradually transformed into finer, shorter, less pigmented hairs; the growth phase shortens, the resting phase proportion rises, and visible density falls.

DHT is produced from testosterone by the enzyme 5α-reductase. Finasteride preferentially inhibits Type II 5α-reductase, reducing DHT in serum and scalp tissue. It has no affinity for the androgen receptor and is not androgenic, antiandrogenic or estrogenic in the receptor-binding sense described in its labelling.

Where a patient sits on the progression scale before starting is set out on our Norwood scale page.

What Finasteride Is Approved For

In the United States, finasteride 1 mg is indicated for male pattern hair loss in men only. It is not indicated for use in women, and exposure in pregnancy is contraindicated because of risk to a male fetus.

Finasteride is also used at 5 mg for benign prostatic hyperplasia. Several safety findings — the PSA effect and the high-grade prostate cancer signal discussed below — come primarily from 5 mg studies but appear in labelling relevant to finasteride use more broadly.

Efficacy and Realistic Timeline

The outcomes that matter clinically are slowing or stopping visible progression, increased density (especially at the crown), improved hair calibre and coverage, and long-term preservation of native hair — the last being particularly important when a transplant is planned.

An international evidence-based guideline update recommends oral finasteride 1 mg/day to improve or prevent progression in adult men with mild to moderate androgenetic alopecia (Hamilton–Norwood IIv–V), with continuation required to maintain efficacy.

Safety: Clinical Trials Versus Postmarketing Reports

Honest safety communication has to reconcile two different kinds of evidence. Controlled trials provide structured incidence estimates. Postmarketing surveillance reveals rare, persistent or unexpected outcomes that may not surface in trials — but cannot always establish causality or frequency.

Adverse reactions in clinical trials (finasteride 1 mg)

From the FDA label, Year 1, reported in at least 1% of patients and more often than placebo:

The label notes that incidence decreased to 0.3% or less by the fifth year of treatment in those studies.

Postmarketing experience

FDA labelling for postmarketing experience includes sexual dysfunction continuing after discontinuation (erectile dysfunction, libido disorders, ejaculation disorders, orgasm disorders); male infertility and/or poor seminal quality, with reports of normalisation or improvement after stopping; testicular pain; hematospermia; male breast cancer; and depression, suicidal ideation and behaviour.

Sexual Side Effects: What We Tell Patients

Patients seeking hair restoration are often highly engaged and anxious about risk, and the possibility of persistent sexual side effects can dominate decision-making. Our position is that credibility comes from precise numbers, acknowledging postmarketing reports without sensationalism, and offering a monitoring plan with clear stop criteria.

Three statements we make, all grounded in labelling: sexual side effects occur in a minority of users and were modestly higher than placebo in trials; most trial-reported sexual side effects resolved either after discontinuation or during continued therapy; and postmarketing reports include cases of persistent sexual dysfunction after stopping, so persistence is possible in some individuals even though frequency cannot be reliably estimated from voluntary reports.

We also place this against baseline: sexual dysfunction is common in the general population, and stress, anxiety and relationship factors contribute. The point of counselling is not to minimise the medication-specific risk but to prevent either-or thinking — and to make clear that the patient can stop and reassess at any time, with clinician guidance.

Psychiatric Safety: Mood, Depression and Suicidality

This is the area where regulatory communication has changed most, and it is the section we will not soften.

Our clinic protocol therefore includes baseline mental health screening questions (history of depression, anxiety, suicidal ideation, current psychiatric treatment); clear counselling that mood changes can occur and should be reported immediately; and a documented plan — if significant mood change occurs, seek medical advice, and depending on clinician judgement and local guidance, discontinuation may be advised, particularly for finasteride 1 mg in hair-loss patients.

This is not fear marketing. It is informed consent and harm minimisation.

Fertility, Semen Exposure and Pregnancy

FDA labelling includes measured semen finasteride levels in men taking 1 mg/day.

This helps clinicians counsel couples realistically, but it does not remove the importance of pregnancy precautions where applicable.

On fertility, postmarketing labelling includes male infertility and/or poor seminal quality, with reports of normalisation or improvement after discontinuation. Reproductive-health literature discusses semen parameter changes and reversibility in some patients. Men actively trying to conceive, or with a history of infertility, should raise this before starting.

PSA and Prostate Cancer Screening

Most finasteride 1 mg users are younger men, but the PSA effect and its disclosure still matter — particularly as patients age or if they undergo prostate evaluation later. Tell any clinician ordering a PSA test that you take finasteride.

Oral Versus Topical Finasteride

Some studies suggest topical finasteride may improve hair parameters. However, high-quality evidence and standardised formulations remain limited, and some guidelines historically made no recommendation for or against topical finasteride because the evidence was insufficient at the time.

The FDA has issued an alert regarding potential risks associated with compounded topical finasteride products, noting reports of adverse events and highlighting that compounded formulations may be marketed alone or combined with minoxidil.

Finasteride and Hair Transplant Surgery

A hair transplant redistributes donor hair. It does not stop androgenetic progression in the native hair around it. Many transplant patients therefore benefit from medical therapy to stabilise progression, preserve native hair and prevent islands of transplanted hair surrounded by continued thinning, and potentially reduce the appearance of shock loss — though this is patient-dependent. Clinical literature includes studies assessing finasteride use around hair transplantation, supporting its role as part of a comprehensive approach for appropriate candidates.

Our own aggregate figures — volume, graft counts, complication and revision rates — are published in the 2025 Annual Clinical Report, and documented cases with standardised follow-up photography are on the before and after page.

Our Counselling and Monitoring Protocol

Before treatment

We confirm the diagnosis is consistent with androgenetic alopecia and consider differential diagnoses where indicated. We document baseline: standardised photographs, Norwood stage, and the patient’s own stated goal — stabilisation, regrowth, or transplant planning. We screen for history of depression or anxiety, prior sexual dysfunction, fertility goals, current medications and hepatic issues. Then we explain the expected timeline, the need for ongoing use, the trial-incidence side effects, the postmarketing risks, and the pregnancy handling precautions.

Follow-up schedule

Patient Questions

When will I see results?

Many patients need at least 3 months before benefits are observed, and meaningful evaluation often requires 6 to 12 months. If treatment is stopped, benefits typically reverse within about 12 months.

What side effects are most common?

In trials the most common — reported in at least 1% of patients and more often than placebo — were decreased libido (1.8% versus 1.3%), erectile dysfunction (1.3% versus 0.7%) and ejaculation disorder (1.2% versus 0.7%).

Can sexual side effects persist after stopping?

Postmarketing reports include sexual dysfunction that continued after discontinuation. Frequency and causality cannot be reliably established from voluntary reports, but patients should be informed and monitored. Persistence is possible in some individuals.

Can finasteride affect mood or mental health?

Postmarketing labelling includes depression and suicidal ideation and behaviour, and regulators in multiple regions have emphasised monitoring for mood changes. The EMA has confirmed suicidal ideation as a side effect with frequency unknown. If mood changes occur, seek medical advice promptly.

Is finasteride safe for women?

Finasteride 1 mg is not indicated for women in FDA labelling. It is contraindicated in pregnancy due to risk to a male fetus, and women should not handle crushed or broken tablets. Treatment options for female pattern hair loss are covered on our hair transplant for women page.

Is topical finasteride safer than oral?

Not necessarily. Systemic absorption may occur, compounded products vary in formulation and quality, and the FDA has raised concerns about potential risks associated with compounded topical finasteride.

Do I still need finasteride if I have a hair transplant?

A transplant moves hair but does not stop ongoing androgenetic alopecia in native hair. Finasteride may help stabilise progression in appropriate candidates and may form part of long-term planning. It is a discussion, not a requirement.

Does finasteride affect PSA tests?

Yes. In men aged 18 to 41 taking 1 mg, mean PSA fell from 0.7 to 0.5 ng/mL at month 12. Always tell a clinician ordering a PSA test that you take finasteride, so the result can be interpreted correctly.

Conclusion

Finasteride remains one of the most studied and widely used medical therapies for male androgenetic alopecia. Its benefits — slowing progression and supporting regrowth in many men — are meaningful, particularly when hair loss is early to moderate and when long-term planning is central to a natural outcome.

But hair restoration is elective care, and trust depends on transparent patient education. A clinic’s responsibility is to communicate evidence and timelines honestly, disclose both trial-based risks and postmarketing concerns, screen appropriately and monitor actively, and respect patient autonomy and individual risk tolerance. If you want to discuss whether medical therapy fits your own plan, contact the clinic.

References

1. US FDA prescribing information (label): PROPECIA (finasteride) tablets, 1 mg; revised 07/2022.
2. EMA (EU): Finasteride- and dutasteride-containing medicinal products — referral and measures to minimise suicidal thoughts risk; CMDh endorsement, June 2025.
3. MHRA (UK): Safety review and public assessment report; risk-minimisation measures related to finasteride psychiatric and sexual side effects, including persistence.
4. Health Canada: Summary Safety Review — Finasteride: assessing potential risks of suicide, suicidal ideation and self-injury; issued 19 January 2023.
5. S3 guideline update (androgenetic alopecia): Evidence summary and therapeutic recommendation for oral finasteride 1 mg/day; assessment at 6 months; continuation required for maintenance; PSA counselling.
6. American Academy of Dermatology: Hair loss — diagnosis and treatment guidance, including evaluation timelines for medical therapies.
7. British Association of Dermatologists: Patient information on finasteride for male pattern hair loss.
8. Leavitt M, et al. Effects of finasteride (1 mg) on hair transplant outcomes. Dermatologic Surgery, 2005.
9. Zhang M, et al. Systematic review and meta-analysis on persistent adverse effects and post-finasteride syndrome-related outcomes, 2021.
10. FDA alert (compounding): Potential risks associated with compounded topical finasteride; adverse event reports and risk concerns.